News | January 20, 2022
Natco Pharma signs agreement with Medicines Patent Pool
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
New capabilities on Philips Image Guided therapy mobile C-arm system – Zenition – and collaboration with Cydar offer the latest advances in endovascular treatment
_256_384.jpg)
Extending nonsurgical treatment options for Failing Pulmonic Valve in patients with congenital heart disease using Transcatheter Pulmonary Valve
The tie-up combines Abbisko Therapeutics’ proprietary drug discovery platform with Lilly’s disease and discovery expertise
Prof Karikó's research was most notably used by Pfizer/BioNTech and Moderna to build COVID-19 mRNA vaccines
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
The company has 271 cumulative ANDA filings with USFDA of which 243 ANDAs have been approved and 28 are pending approval
Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation
Subscribe To Our Newsletter & Stay Updated
